A Phase 3 interventional study of Ibuprofen and Placebo in Infection, sponsored by Pfizer. Terminated at 5 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-08-21.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This single-dose trial will evaluate the efficacy of a novel ibuprofen formulation compared to placebo in patients with a fever due to an uncomplicated acute infection.
2,096 studies on the registry are indexed under Infections; 362 are open to participants now.
This study's enrollment of 16 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ibuprofen
Drug: Placebo
Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
Single dose of a placebo
Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)
STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.
Time frame: 0 to 6 hours
Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)
STEMPD 0-4 and STEMPD 0-8 were defined as the time-weighted sum of temperature differences over 4 hours and 8 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.
Time frame: 0 to 4, 0 to 8 hours
Change From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8
Change from baseline in temperature was calculated as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.
Time frame: Baseline, 0.25, 0.5, 1, 2, 4, 6, 8 hours
Time to Treatment Failure
Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first.
Time frame: 0 to 8 hours
Cumulative Percentage of Participants With Treatment Failure
Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication.
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8 hours
Global Assessment of Study Medication as an Antipyretic
Global assessment of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.
Time frame: 8 hours
Rating of Study Medication Relative to Usual Medication
Rating of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.
Time frame: 8 hours
| Milestone | Placebo | Ibuprofen Sodium |
|---|---|---|
| Started | 7 | 9 |
| Completed | 7 | 9 |
| Not completed | 0 | 0 |
STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.
| Degrees Fahrenheit | Placebo | Ibuprofen Sodium |
|---|---|---|
| Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6) | 3.0 ± 6.3 | 10.8 ± 4.9 |
STEMPD 0-4 and STEMPD 0-8 were defined as the time-weighted sum of temperature differences over 4 hours and 8 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.
| Degrees Fahrenheit | Placebo | Ibuprofen Sodium |
|---|---|---|
| STEMPD 0-4 | 1.7 ± 3.9 | 6.7 ± 2.9 |
| STEMPD 0-8 | 5.7 ± 9.4 | 13.4 ± 7.3 |
Change from baseline in temperature was calculated as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.
| Degrees Fahrenheit | Placebo | Ibuprofen Sodium |
|---|---|---|
| 0.25 hours | 0.4 ± 0.4 | 0.4 ± 0.3 |
| 0.5 hours | 0.5 ± 0.4 | 0.7 ± 0.4 |
| 1 hour | 0.3 ± 0.7 | 1.2 ± 0.7 |
| 2 hours | 0.8 ± 1.0 | 1.9 ± 0.9 |
| 4 hours | 0.3 ± 1.5 | 2.0 ± 0.9 |
| 6 hours | 0.7 ± 1.5 | 2.1 ± 1.3 |
| 8 hours | 1.3 ± 1.7 | 1.3 ± 1.9 |
Median time of dropping out of the participants from the study due to lack of efficacy or use of rescue medication, whichever comes first.
| hours | Placebo | Ibuprofen Sodium |
|---|---|---|
| Time to Treatment Failure | NA (NA to NA) | NA (NA to NA) |
Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication.
| percentage of participants | Placebo | Ibuprofen Sodium |
|---|---|---|
| 0.25 hours | 0.0 | 0.0 |
| 0.5 hours | 0.0 | 0.0 |
| 1 hour | 0.0 | 0.0 |
| 2 hours | 0.0 | 0.0 |
| 4 hours | 0.0 | 0.0 |
| 6 hours | 0.0 | 0.0 |
| 8 hours | 0.0 | 11.1 |
Global assessment of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.
| units on a scale | Placebo | Ibuprofen Sodium |
|---|---|---|
| Global Assessment of Study Medication as an Antipyretic | 1.8 ± 1.5 | 2.5 ± 1.1 |
Rating of study medication was performed at the 8-hours time point or immediately before taking rescue medication (if necessary). It was scored on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.
| units on a scale | Placebo | Ibuprofen Sodium |
|---|---|---|
| Rating of Study Medication Relative to Usual Medication | 1.5 ± 1.4 | 2.4 ± 1.1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/7 (0%) | 1/7 (14.3%) |
| Ibuprofen Sodium | — | 0/9 (0%) | 3/9 (33.3%) |
| Event | Placebo | Ibuprofen Sodium |
|---|---|---|
| PainGeneral disorders | 1/7 | 0/9 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/7 | 0/9 |
| Cold sweatGeneral disorders | 0/7 | 1/9 |
| FatigueGeneral disorders | 0/7 | 1/9 |
| MalaiseGeneral disorders | 0/7 | 1/9 |
| PruritusSkin and subcutaneous tissue disorders | 0/7 | 1/9 |
| Age Continuous(years) | Placebo | Ibuprofen Sodium | Total |
|---|---|---|---|
| Mean | 31.4 ± 15.3 | 37.3 ± 17.9 | 34.8 ± 16.5 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen Sodium | Total |
|---|---|---|---|
| Female | 2 | 4 | 6 |
| Male | 5 | 5 | 10 |
| Body Temperature(Degrees Fahrenheit) | Placebo | Ibuprofen Sodium | Total |
|---|---|---|---|
| Mean | 100.99 ± 0.83 | 100.58 ± 0.66 | 100.76 ± 0.74 |
The record gives a start of Jan 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen